BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cervo A, Milic J, Mazzola G, Schepis F, Petta S, Krahn T, Lebouche B, Deschenes M, Cascio A, Guaraldi G, Sebastiani G. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. Clin Infect Dis 2020;71:e694-701. [PMID: 32280969 DOI: 10.1093/cid/ciaa430] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Davies C, Vaida F, Otwombe K, Cotton MF, Browne S, Innes S. Longitudinal comparison of insulin resistance and dyslipidemia in children with and without perinatal HIV infection in South Africa. AIDS 2023;37:523-33. [PMID: 36695362 DOI: 10.1097/QAD.0000000000003452] [Reference Citation Analysis]
2 Sebastiani G, Paisible N, Costiniuk C, Cox J, Kablawi D, Klein MB, Kronfli N, Routy J, Falutz J, Lebouché B, Guaraldi G. The Relationship between Visceral Adiposity and Nonalcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter in People with HIV: A Pilot Study. Diagnostics 2022;12:2590. [DOI: 10.3390/diagnostics12112590] [Reference Citation Analysis]
3 Sebastiani G, Sebastiani G. Fatty liver in children with HIV: a clinical iceberg? AIDS 2022;36:1469-71. [PMID: 35876707 DOI: 10.1097/QAD.0000000000003251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Carrasco I, Olveira A, Lancharro Á, Escosa L, Mellado MJ, Busca C, Montes ML, Díez C, Alcolea-Ruiz S, Navarro ML, Sáinz T. Fatty liver disease in children living with HIV: a ghostly iceberg. AIDS 2022;36:1471-2. [PMID: 35876708 DOI: 10.1097/QAD.0000000000003250] [Reference Citation Analysis]
5 Martínez-sanz J, Calvo MV, Serrano-villar S, Montes ML, Martín-mateos R, Burgos-santamaría D, Díaz-álvarez J, Talavera-rodríguez A, Rosas M, Moreno S, Fontecha J, Sánchez-conde M. Effects of HIV Infection in Plasma Free Fatty Acid Profiles among People with Non-Alcoholic Fatty Liver Disease. JCM 2022;11:3842. [DOI: 10.3390/jcm11133842] [Reference Citation Analysis]
6 Lemoine M, Assoumou L, Girard PM, Valantin MA, Katlama C, De Wit S, Campa P, Rougier H, Meynard JL, Necsoi C, Huefner AD, Van Luzen J, Schulze Zur Wiesch J, Bastard JP, Fellahi S, Mauss S, Stankov MV, Baumgarten A, Post G, Serfaty L, Ratziu V, Menu Y, Schlue J, Bedossa P, Capeau J, Costagliola D, Behrens G, Ingiliz P; ANRS-ECHAM group. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00390-1. [PMID: 35436624 DOI: 10.1016/j.cgh.2022.03.048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Price J, Ma Y, Adimora A, Fischl M, French AL, Golub ET, Konkle-Parker D, Kuniholm MH, Ofotokun I, Plankey M, Sharma A, Tien PC. Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV. BMJ Open 2022;12:e055706. [PMID: 35393310 DOI: 10.1136/bmjopen-2021-055706] [Reference Citation Analysis]
8 Cervo A, Sebastiani G, Milic J, Krahn T, Mazzola S, Petta S, Cascio A, Guaraldi G, Mazzola G. "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV". HIV Med 2022. [PMID: 35199429 DOI: 10.1111/hiv.13274] [Reference Citation Analysis]
9 Rossetti B, Borgo V, Emiliozzi A, Colaneri M, Zanelli G, d’Alessandro M, Motta D, Maiocchi L, Montagnani F, Moioli MC, Baiguera C, Sambo M, Pieri TC, Valsecchi P, Bruno R, Puoti M, Fabbiani M. Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. Diagnostics 2021;12:14. [DOI: 10.3390/diagnostics12010014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K, Dold L, Rockstroh JK, Trebicka J. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine 2021;40:101116. [PMID: 34522873 DOI: 10.1016/j.eclinm.2021.101116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
11 Williams C, Kamau FM, Everson F, Kgokane B, De Boever P, Goswami N, Webster I, Strijdom H. HIV and Antiretroviral Therapy Are Independently Associated with Cardiometabolic Variables and Cardiac Electrical Activity in Adults from the Western Cape Region of South Africa. J Clin Med 2021;10:4112. [PMID: 34575223 DOI: 10.3390/jcm10184112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Hanttu A, Vuoti S, Kivelä P, Arkkila P, Lundbom N, Hakkarainen A, Lundbom J, Lehtimäki T, Viskari H, Lehtinen V, Pietiläinen KH, Sutinen J. Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir. AIDS Patient Care STDS 2021;35:335-41. [PMID: 34524919 DOI: 10.1089/apc.2021.0106] [Reference Citation Analysis]
13 Heseltine T, Murray S, Ortega-Martorell S, Olier I, Lip GYH, Khoo S. Associations of Hepatosteatosis With Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV-Heart Project. J Acquir Immune Defic Syndr 2021;87:1221-7. [PMID: 33990492 DOI: 10.1097/QAI.0000000000002721] [Reference Citation Analysis]
14 Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020;17:601-14. [PMID: 32984925 DOI: 10.1007/s11904-020-00531-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
15 Ferraioli G. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason (2001) 2021;48:489-95. [PMID: 34132934 DOI: 10.1007/s10396-021-01106-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]